• Invivyd reported past Q1 2026 results showing revenue of US$13.74 million versus US$11.30 million a year earlier, alongside a wider net loss of US$41.40 million, and also registered a US$36.43 million common stock shelf for an ESOP-related offering.
• Alongside these financial moves, Invivyd highlighted new research suggesting its COVID monoclonal antibody had markedly fewer early systemic reactions than common vaccine regimens, and outlined plans for the LIBERTY study to directly compare symptoms after mRNA vaccination and its VYD2311 candidate.
• Against this backdrop, we’ll now assess how Invivyd’s widened quarterly loss but encouraging monoclonal antibody tolerability data influence its investment narrative.

AI is about to change healthcare. These 34 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

Invivyd Investment Narrative Recap

To own Invivyd today, you need to believe that antibody-based prevention for infectious diseases can become a meaningful, durable niche despite a still COVID-heavy portfolio and ongoing losses. The latest Q1 2026 results, with higher revenue but a much wider net loss, reinforce that near term execution risk sits around cash burn and trial progress, while the key catalyst remains VYD2311’s clinical and regulatory path. The new data do not materially change those near term priorities.

The newly highlighted tolerability data from the EVADE trial, and plans for the LIBERTY study comparing mRNA vaccines with VYD2311, are most relevant right now. If LIBERTY confirms a clear tolerability edge in a controlled setting, it could strengthen Invivyd’s case with regulators and patients for COVID prevention options beyond vaccination, which sits directly against the main catalyst of converting its monoclonal antibody science into a more resilient, multi-product franchise.

Yet against this progress, investors should also weigh the risk that rising losses and potential dilution from the new US$36.43 million shelf could...

Invivyd's narrative projects $206.4 million revenue and $26.4 million earnings by 2029.

Uncover how Invivyd's forecasts yield a $10.00 fair value, a 762% upside to its current price.

Exploring Other Perspectives

By contrast, the most pessimistic analysts were already modeling steep growth to about US$345.1 million revenue and US$25.4 million earnings by 2028, so this quarter’s wider loss and ongoing regulatory uncertainty around PEMGARDA and VYD2311 may lead them, and you, to revisit how realistic those assumptions really feel.

Explore 7 other fair value estimates on Invivyd - why the stock might be worth 14% less than the current price!

Reach Your Own Conclusion

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Invivyd research is our analysis highlighting 4 key rewards and 3 important warning signs that could impact your investment decision.
• Our free Invivyd research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Invivyd's overall financial health at a glance.

Ready To Venture Into Other Investment Styles?

Don't miss your shot at the next 10-bagger. Our latest stock picks just dropped:

• Invest in the nuclear renaissance through our list of 87 elite nuclear energy infrastructure plays powering the global AI revolution.
• The future of work is here. Discover the 32 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
• Rare earth metals are the new gold rush. Find out which 33 stocks are leading the charge.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.